medigraphic.com
ISSN 2174-0798 (Print)
Organo oficial de la Asociación Latinoamericana de Odontopediatría (ALOP)

2021, Number 2

<< Back Next >>

Rev Odotopediatr Latinoam 2021; 11 (2)

Bisphosphonates in pediatric dentistry: literature review, management protocol and report of a clinical case

Báez MI, López FR, Téllez RJP

Language: Spanish
References: 22
Page: 335-344
PDF size: 465.46 Kb.


ABSTRACT

Bisphosphonates are currently used in the pediatric population diagnosed with osteogenesis imperfecta, neuromuscular disorders, skeletal dysplasia, fibrous dysplasia, juvenile idiopathic osteoporosis, Crohn’s disease, and rheumatologic disorders. Bisphosphonate-related osteonecrosis of the jaw has become an increasingly common complication due to its increased use in the adult population. Regarding pediatric care, information is scarce. This study presents the clinical case of a female patient diagnosed with type III osteogenesis imperfecta who was treated with multiple dental extractions under general anesthesia, after administration of amoxicillin 50 mg/kg 1 hour before; due to anomalous eruption of upper canines and first premolars, as well as persistence of upper primary canines and molars. Postoperative control appointments were made, where she showed an adequate healing process without evidence of maxillary necrosis. The aim is to inform the stomatologist about how bisphosphonates act, the diagnoses in the pediatric population treated with this drug and to present the management protocol for these patients. An integrative review was carried out in the PubMed and Cochrane Library databases, the articles were selected according to the established criteria.


REFERENCES

  1. Gasser JA, Kneissel M. Bone Physiology and Biology. En: Smith SY, Varela A, Samadfam R. Bone Toxicology. XII ed. Montreal, Canada. Springer International 2017:27-94.

  2. Dominguez L, Di Bella G, Belvedere M, Barbagallo M. Physiology of the aging bone and mechanisms of action of bisphosphonates. Biogerontology 2011;12:397-408. DOI 10.1007/s10522-011-9344-5

  3. Batt RN, Hibbert SA, Munns CF. The use of bisphosphonates in children: review of the literature and guidelines for dental management. Aust Dent J 2014;59:9–19. DOI: 10.1111/adj.12140

  4. Bourgeois AB, Aubry-Rozier B, Bonafé L, et al. Osteogenesis imperfecta: from diagnosis and multidisciplinary treatment to future perspectives. Swiss Med Wkly 2016;146:1

  5. Eghbali-Fatourechi G. Bisphosphonate therapy in pediatric patients. J Diabetes Metab Disord. 2014;13:109.

  6. Endo Y, Kumamoto H, Nakamura M, et al. Underlying Mechanisms and Therpeutic Strategies for Bisphosphonate-Related Osteonecrosis of the jaw (BRONJ). Biol. Pharm. Bull 2017;40:739-750.

  7. Dwan K, Phillipi CA, Steiner RD, Basel D. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database of Systematic Reviews 2016;10:1-71. DOI: 10.1002/14651858.CD005088.pub4.

  8. Ngan K-K, Bowe J, Goodger N. The Risk of Bisphosphoate Related Osteonecrosis of the Jaw in Children. A Case Report and Literature Review. Dent Update 2013;40:733–738.

  9. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479–1491.

  10. Khan AA, Sandor GK, Dore E, et al. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2008;35:1391–1397.

  11. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws 2009 update. J Oral Maxillofac Surg 2009;67:2–12.

  12. Sambrook P, Olver I, Goss A. Bisphosphonates and osteonecrosis of the jaw. Aust Fam Physician 2006;35:801–803.

  13. Malmgren B, Astrom E, Soderhall S. No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates. J Oral Pathol Med 2008; 37:196-200.

  14. Brown JJ, Ramalingam L, Zacharin MR. Bisphosphonate associated osteonecrosis of the jaw: does it occur in children? Clin Endocrinol (Oxf) 2008;68:863–867.

  15. Chahine C, Cheung MS, Head TW, Schwartz S, Glorieux FH, Rauch F. Tooth extraction socket healing in pediatric patients treated with intravenous pamidronate. J Pediatr 2008;153:719–720.

  16. Schwartz S, Joseph C, Iera D, Vu D-D. Bisphosphonates, osteonecrosis, osteogenesis imperfecta and dental extractions: a case series. J Can Dent Assoc 2008;74:537–542.

  17. Grier RL, Wise GE. Inhibition of tooth eruption in the rat by a bisphosphonate. J Dent Res 1998;77:8–15.

  18. Bradaschia-Correa V, Massa LF, Arana-Chavez VE. Effects of alendronate on tooth eruption and molar root formation in young growing rats. Cell Tissue Res 2007;330:475-485.

  19. Hiraga T, Ninomiya T, Hosoya A, Nakamura H. Administration of the bisphosphonate zoledronic acid during tooth development inhibits tooth eruption and formation and induces dental abnormalities in rats. Calcif Tissue Int 2010;86:502–510.

  20. Lotwala RB, Greenlee GM, Ott SM, Hall SH, Huang GJ. Bisphosphonates as a risk factor for adverse orthodontic outcomes: a retrospective cohort study. Am J Orthod Dentofacial Orthop 2012;142:625–634.

  21. Ghoneima AA, Allam ES, Zunt SL, Windsor LJ. Bisphosphonates treatment and orthodontic considerations. Orthod Cranio- fac Res 2010;13:1–10.

  22. Hennedige AA, Jayasinghe J, Khajeh J, Macfarlane TV. Systematic Review on the Incidence of Bisphosphonate Related Osteonecrosis of the Jaw in Children Diagnosed with Osteogenesis Imperfecta. J Oral Maxillofac Res 2013;4(4):e1 Disponible en: http://www.ejomr.org/JOMR/archives/2013/4/e1/v4n4e1ht.pdf




2020     |     www.medigraphic.com